Hypophosphatemia: Difference between revisions
| Line 11: | Line 11: | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
===Causes of Hypophosphatemia=== | |||
*Internal redistribution | *Internal redistribution | ||
**Refeeding of malnourished | **Refeeding of malnourished | ||
| Line 16: | Line 17: | ||
**[[Nonketotic hyperglycemia]] | **[[Nonketotic hyperglycemia]] | ||
**Receiving hyperalimentation | **Receiving hyperalimentation | ||
**Acute respiratory alkalosis | **Acute [[respiratory alkalosis]] | ||
**Hungry bone syndrome | **Hungry bone syndrome | ||
*Decreased intestinal absorption | *Decreased intestinal absorption | ||
**Inadequate intake | **Inadequate intake | ||
**Antacids containing aluminum or magnesium | **Antacids containing aluminum or magnesium | ||
**Steatorrhea and/or chronic diarrhea | **Steatorrhea and/or chronic [[diarrhea]] | ||
*Increased urinary excretion | *Increased urinary excretion | ||
**Vitamin D deficiency or resistance | **Vitamin D deficiency or resistance | ||
**Primary renal phosphate wasting (rare genetic disorders) | **Primary renal phosphate wasting (rare genetic disorders) | ||
**Fanconi syndrome | **[[Fanconi syndrome]] | ||
***Multiple myeloma | ***[[Multiple myeloma]] | ||
**Osmotic diuresis (most often due to glucosuria) | **Osmotic diuresis (most often due to glucosuria) | ||
**Proximally acting diuretics (e.g. acetazolamide and some thiazide diuretics) | **Proximally acting diuretics (e.g. [[acetazolamide]] and some [[thiazide diuretics]]) | ||
**Acute volume expansion | **Acute volume expansion | ||
**Intravenous iron administration | **Intravenous iron administration | ||
Revision as of 13:29, 26 August 2015
Background
Clinical Features
- CNS
- Weakness
- Circumoral and fingertip paresthesias
- Decreased DTRs
- Decreased Mental Status
- Cardiac
- Impaired myocardial function
Differential Diagnosis
Causes of Hypophosphatemia
- Internal redistribution
- Refeeding of malnourished
- DKA
- Nonketotic hyperglycemia
- Receiving hyperalimentation
- Acute respiratory alkalosis
- Hungry bone syndrome
- Decreased intestinal absorption
- Inadequate intake
- Antacids containing aluminum or magnesium
- Steatorrhea and/or chronic diarrhea
- Increased urinary excretion
- Vitamin D deficiency or resistance
- Primary renal phosphate wasting (rare genetic disorders)
- Fanconi syndrome
- Osmotic diuresis (most often due to glucosuria)
- Proximally acting diuretics (e.g. acetazolamide and some thiazide diuretics)
- Acute volume expansion
- Intravenous iron administration
- Renal replacement therapy
Diagnosis
- 2.5-2.8 Mild
- 1.0-2.5 Mod
- <1.0 Severe
Treatment
- Mild-mod
- KPhos /neutra phos PO
- Severe
- KPhos 2.5-5 mg/kg IV over 6hr
Harbor UCLA Adult Treatment Guidelines
- Serum phosphate 1 mg/dl to 2 mg/dl
- Able to take PO
- Minimize or eliminate all dextrose-containing IV solutions
- Aggressively treat acidosis
- 1 tab K-phos neutral 250mg Q hour x 5 doses
- Each tab contains phosphorus 8 mmol, Na 13 mEq, K1.1 mEq
- Recheck serum phosphate after last dose, and repeat dosing if continues to be <2 mg/dl
- NOT able to take PO
- Minimize or eliminate all dextrose-containing IV solutions
- Aggressively treat acidosis
- Give 15 mmol of IV potassium phosphate over 2.5 hours (contains 22 mEq K)
- Peripheral administration may cause burning at injection site
- Consider central venous administration, if available
- Repeat dosing regimen if serum phosphate remains <2 mg/dl
- Able to take PO
- Serum phosphate <1 mg/dl
- Minimize or eliminate all dextrose-containing IV solutions
- Exceptions: vasopressors, sedatives, analgesics, antibiotics, blood products, NS
- Aggressively treat acidosis
- Give 45 mmol of IV potassium phosphate over 7 hours (contains 66 mEq of K)
- Peripheral administration may cause burning at injection site
- Consider central venous administration, if available
- If patient can tolerat PO, ALSO follow steps 1 above
- Recheck serum phosphate after infusion
- Repeat IV administration if <1 mg/dl
- Consider oral administration if >1mg and <2 mg/dl
- Minimize or eliminate all dextrose-containing IV solutions
